Macular Degeneration Treatment Market Size, Share, And Growth Report 2032

Macular Degeneration Treatment Market: Size

The global Macular Degeneration Treatment Market size was worth around USD 10.02 billion in 2023 and is predicted to grow to around USD 20.54 billion by 2032 with a compound annual growth rate (CAGR) of roughly 8.3% between 2024 and 2032.

The study provides historical data from 2018 to 2022 along with a forecast from 2024 to 2032 based on revenue (USD billion). The report covers a forecast and an analysis of the Macular Degeneration Treatment Market on a global and regional level.

Request Free Sample

Macular Degeneration Treatment Market: Overview

Macular degeneration is one of major eye disorder and a leading cause of vision loss, affecting people more than cataracts and glaucoma together. Currently, macular degeneration cannot be cured i.e. it is an incurable disease. Deterioration of central portion of the retina called macula leads to macular degeneration. Retina records images we see and signal is sent to brain via optic nerve. Macula is responsible for central vision focusing in the eye. Macula also controls our ability to recognize colors or faces, ability to read, and see objects with fine details.

The demand for macular degeneration treatment market is driven by increasing prevalence of eye disorders, age related macular degeneration and increasing geriatric population across the globe. Additionally, focus of major pharmaceutical manufacturers on development of novel treatment options, increasing awareness, government initiatives to support R&D, and increasing healthcare spending are other factors that boost the market growth. However, growing off-label use of products may hamper the market growth. Emerging markets with unmet medical needs and increasing geriatric population are expected to bring new growth avenues for major market players working in the global macular degeneration treatment.

Macular Degeneration Treatment Market: Segmentation

The study provides a crucial view on the macular degeneration treatment by segmenting the market based on drug class, indication, distribution channel and region. All the segments of macular degeneration treatment market have been analyzed based on present and future trends and the market is estimated from 2024 to 2032.

Based on drug class, global macular degeneration treatment market is bifurcated into anti-vascular endothelial growth factor (VEGFs), and other drugs. Anti-VEGFs accounted for largest market share in 2023 and are projected to witness rapid CAGR over the forecast period as they are considered as gold standard therapy for macular degeneration.

Based on indication market is segmented into Wet Age-related Macular Degeneration (wAMD) and Dry Age-related Macular Degeneration (dAMD). wAMD indication segment accounted for largest market share in 2023 due to large number of ongoing research activities for novel therapy development for wAMD. Favorable reimbursement policies may further boost this growth over the forecast period.

The distribution channel segment is divided ambulatory surgical centers, ophthalmic clinics and hospitals. Hospitals dominated the macular degeneration treatment market to ease of access to hospitals and availability of technologically advanced facilities. Ophthalmic clinics are projected to witness rapid growth over the forecast period.

Macular Degeneration Treatment Market: Report Scope

Macular Degeneration Treatment Market: Regional Analysis

North America dominated the global macular degeneration treatment market in 2023. Increasing prevalence of eye disorders, increasing geriatric population, favorable reimbursement policies, and growing awareness are factors driving the market in this region. Europe was second largest regional market. Availability of developed infrastructure, increasing awareness and prevalence of eye disorders are some of the factors that fuel market growth in this region. Latin America is projected to witness moderate growth over the forecast period. Asia Pacific region is estimated to witness highest CAGR for macular degeneration treatment market in the coming years. Increasing prevalence of age related macular degeneration in geriatric population, increasing disposable income, health care spending, and growing awareness are factors promoting macular degeneration treatment market growth in Asia Pacific. Middle East and Africa will see considerable growth in coming years.

Macular Degeneration Treatment Market: Competitive Players

Major players included in the report are:

• Valeant Pharmaceuticals
• Santen Pharmaceuticals
• Pfizer Inc.
• Sanofi
• F. Hoffmann-La Roche
• StemCells
• Neurotech Pharmaceuticals
• Ophthotech Corporation
• Bayer AG
• GlaxoSmithKline
• Allergan 
• Novartis

The Global Macular Degeneration Treatment Market is segmented as follows:

Global Macular Degeneration Treatment Market: By Drug Class

• Anti-vascular Endothelial Growth Factor (VEGFs)
• Other Drugs

Global Macular Degeneration Treatment Market: By Indication

• Wet Age-related Macular Degeneration (wAMD)
• Dry Age-related Macular Degeneration (dAMD)

Global Macular Degeneration Treatment Market: By Distribution Channel

• Ambulatory Surgical Centers
• Ophthalmic Clinics
• Hospitals

Global Macular Degeneration Treatment Market: By Region

• North America
  • U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• Middle East and Africa